Literature DB >> 25805937

Hepatectomy vs radiofrequency ablation for colorectal liver metastasis: a propensity score analysis.

Huisong Lee1, Jin Seok Heo1, Yong Beom Cho1, Seong Hyeon Yun1, Hee Cheol Kim1, Woo Yong Lee1, Seong Ho Choi1, Dong Wook Choi1.   

Abstract

AIM: To compare outcomes from radiofrequency ablation (RFA) and hepatectomy for treatment of colorectal liver metastasis (CRLM).
METHODS: From January 2000 to December 2009, 408 patients underwent curative intent treatment for CRLM. We excluded patients using the criteria: size of CRLM > 3 cm, number of CRLM ≥ 5, percutaneous RFA, follow-up period < 12 mo, double primary cancer, or treatment with both RFA and hepatectomy. We matched 51 patients who underwent RFA with 102 patients who underwent hepatectomy by propensity scores.
RESULTS: The median follow-up period was 45 mo (range, 12 mo to 158 mo). Hepatic recurrence was more frequent in the RFA than the hepatectomy group (P = 0.021) although extrahepatic recurrence curves were similar (P = 0.716). Survival curves of hepatectomy group were better than that of RFA for multiple, large (> 2 cm) CRLM (P = 0.034). However, survival curves were similar for single or small (≤ 2 cm) CRLM (P = 0.714, P = 0.740).
CONCLUSION: Hepatectomy is better than RFA for the treatment of CRLM. However, RFA might be suitable for selected patients with single, small (≤ 2 cm) CRLM.

Entities:  

Keywords:  Catheter ablation; Colorectal neoplasm; Hepatectomy; Liver; Metastasis

Mesh:

Year:  2015        PMID: 25805937      PMCID: PMC4363760          DOI: 10.3748/wjg.v21.i11.3300

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention.

Authors:  A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol
Journal:  Br J Radiol       Date:  2010-12-15       Impact factor: 3.039

Review 2.  Ablative therapies for colorectal liver metastases: a systematic review.

Authors:  S Pathak; R Jones; J M F Tang; C Parmar; S Fenwick; H Malik; G Poston
Journal:  Colorectal Dis       Date:  2011-09       Impact factor: 3.788

3.  Selection for hepatic resection of colorectal liver metastases: expert consensus statement.

Authors:  Reid B Adams; Thomas A Aloia; Evelyne Loyer; Timothy M Pawlik; Bachir Taouli; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2013-02       Impact factor: 3.647

4.  Comparison between percutaneous radiofrequency ablation and surgical hepatectomy focusing on local disease control rate for colorectal liver metastases.

Authors:  Satoshi Nishiwada; Saiho Ko; Tomohide Mukogawa; Hirofumi Ishikawa; Masanori Matsusaka; Toshiya Nakatani; Eiryo Kikuchi; Akihiko Watanabe
Journal:  Hepatogastroenterology       Date:  2014 Mar-Apr

5.  Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function: a retrospective study using propensity score analyses.

Authors:  Yun-Hsuan Lee; Chia-Yang Hsu; Chen-Wei Chu; Po-Hong Liu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Yi-You Chiou; Han-Chieh Lin; Teh-Ia Huo
Journal:  J Clin Gastroenterol       Date:  2015-03       Impact factor: 3.062

6.  Microwave ablation for hepatic malignancies: a multiinstitutional analysis.

Authors:  Ryan T Groeschl; Charles H C Pilgrim; Erin M Hanna; Kerri A Simo; Ryan Z Swan; David Sindram; John B Martinie; David A Iannitti; Mark Bloomston; Carl Schmidt; Hooman Khabiri; Lawrence A Shirley; Robert C G Martin; Susan Tsai; Kiran K Turaga; Kathleen K Christians; William S Rilling; T Clark Gamblin
Journal:  Ann Surg       Date:  2014-06       Impact factor: 12.969

Review 7.  Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? An update.

Authors:  Stefaan Mulier; Theo Ruers; Jacques Jamart; Luc Michel; Guy Marchal; Yicheng Ni
Journal:  Dig Surg       Date:  2009-02-12       Impact factor: 2.588

8.  Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases.

Authors:  Sanghwa Ko; Hongjae Jo; Seongpil Yun; Eunyoung Park; Suk Kim; Hyung-Il Seo
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

9.  Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases.

Authors:  Hyuk Hur; Yong Taek Ko; Byung Soh Min; Kyung Sik Kim; Jin Sub Choi; Seung Kook Sohn; Chang Hwan Cho; Heung Kyu Ko; Jong Tai Lee; Nam Kyu Kim
Journal:  Am J Surg       Date:  2008-09-11       Impact factor: 2.565

10.  Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation.

Authors:  Anna Maria Ierardi; Chiara Floridi; Federico Fontana; Claudio Chini; Francesca Giorlando; Filippo Piacentino; Luca Brunese; Graziella Pinotti; Alessandro Bacuzzi; Gianpaolo Carrafiello
Journal:  Radiol Med       Date:  2013-07-20       Impact factor: 3.469

View more
  17 in total

Review 1.  Defining the Optimal Use of Ablation for Metastatic Colorectal Cancer to the Liver Without High-Level Evidence.

Authors:  Rafael Diaz-Nieto; Stephen Fenwick; Hassan Malik; Graeme Poston
Journal:  Curr Treat Options Oncol       Date:  2017-02

2.  Current strategies in interventional oncology of colorectal liver metastases.

Authors:  Tatjana Gruber-Rouh; Christian Marko; Axel Thalhammer; Nour-Eldin Nour-Eldin; Marcel Langenbach; Martin Beeres; Nagy N Naguib; Stephan Zangos; Thomas J Vogl
Journal:  Br J Radiol       Date:  2016-05-26       Impact factor: 3.039

Review 3.  Staged resection of bilobar colorectal liver metastases: surgical strategies.

Authors:  Cui Yang; Nuh N Rahbari; Sören Torge Mees; Felix Schaab; Moritz Koch; Jürgen Weitz; Christoph Reissfelder
Journal:  Langenbecks Arch Surg       Date:  2015-06-08       Impact factor: 3.445

Review 4.  Thermal Ablation of Metastatic Colon Cancer to the Liver.

Authors:  Juan C Camacho; Elena N Petre; Constantinos T Sofocleous
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

5.  Extreme liver surgery as treatment of liver tumors involving the hepatocaval confluence.

Authors:  C Codony; S López-Ben; M Albiol; L Falgueras; E Castro; A Codina-Barreras; M Casellas; J Gil; A Codina-Cazador; J Figueras
Journal:  Clin Transl Oncol       Date:  2016-03-10       Impact factor: 3.405

6.  Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases.

Authors:  Guillaume Passot; Yun Shin Chun; Scott E Kopetz; Daria Zorzi; Kristoffer Watten Brudvik; Bradford J Kim; Claudius Conrad; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2016-01-18       Impact factor: 6.113

Review 7.  Radiofrequency Ablation versus Liver Resection for Colorectal Cancer Liver Metastasis: An Updated Systematic Review and Meta-analysis.

Authors:  Yue Han; Dong Yan; Fei Xu; Xiao Li; Jian-Qiang Cai
Journal:  Chin Med J (Engl)       Date:  2016-12-20       Impact factor: 2.628

8.  Streamline flow of the portal vein affects the lobar distribution of colorectal liver metastases and has a clinical impact on survival.

Authors:  Jinsoo Rhu; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi; Jong Man Kim; Jae-Won Joh; Choon Hyuck David Kwon
Journal:  Ann Surg Treat Res       Date:  2017-04-27       Impact factor: 1.859

9.  The role of surgical intervention for isolated breast cancer liver metastasis: Results of case-control study with comparison to medical treatment.

Authors:  Jiahuai Wen; Feng Ye; Fengfeng Xie; Dan Liu; LeZhen Huang; Chen Fang; Shaowen Zhong; Liping Ren
Journal:  Cancer Med       Date:  2020-05-12       Impact factor: 4.452

10.  Percutaneous Microwave Ablation Versus Open Surgical Resection for Colorectal Cancer Liver Metastasis.

Authors:  Qinxian Zhao; Zhigang Cheng; Zhiyu Han; Fangyi Liu; Xiaoling Yu; Xianliang Tan; Bin Han; Jianping Dou; Jie Yu; Ping Liang
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.